Disease · MONDO_0033821
fungal keratitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. fungal keratitis. Diseases, record MONDO_0033821. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0033821
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NATAMYCIN | CHEMBL1200656 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| VORICONAZOLE | CHEMBL638 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| MOXIFLOXACIN | CHEMBL32 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AMPHOTERICIN B | CHEMBL267345 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHLORHEXIDINE GLUCONATE | CHEMBL4297088 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROSE BENGAL FREE ACID | CHEMBL1208422 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POVIDONE-IODINE | CHEMBL1201724 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| RIBOFLAVIN | CHEMBL1534 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEFTAZIDIME | CHEMBL44354 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| PPIA | Peptidyl-prolyl cis-trans isomerase A | 1 | Cyclophilin A modulator | Phase 3 | https://conductscience.org/library/genes/5478 |
Source Drugs and targets
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05110001 | Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction | Phase 3 | 330 | 2026-01-30 | Acanthamoeba Keratitis, Fungal Keratitis | CHLORHEXIDINE GLUCONATE, MOXIFLOXACIN, NATAMYCIN, ROSE BENGAL FREE ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00996736 | Mycotic Ulcer Treatment Trial I | Phase 3 | 323 | 2013-12-11 | Corneal Ulcer, Eye Infections, Fungal | NATAMYCIN, VORICONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02570321 | Cross-linking for Corneal Ulcers Treatment Trial | Phase 3 | 147 | 2024-08-27 | Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer | AMPHOTERICIN B, MOXIFLOXACIN, NATAMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02731638 | Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers | Phase 3 | 70 | 2019-10-01 | Corneal Ulcer, Fungal Keratitis | NATAMYCIN, VORICONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT06658002 | Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A | Phase 3 | 150 | Fungal Keratitis, Corneal Ulcer | CYCLOSPORINE, NATAMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05655689 | The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study | 123 | Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis, Microbial Keratitis | CEFTAZIDIME, GENTAMICIN, MOXIFLOXACIN, NATAMYCIN, VANCOMYCIN, VORICONAZOLE | Its record names the disease | ClinicalTrials.gov | ||
| NCT06463678 | Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis | Phase 2 | 60 | Fungal Keratitis | POVIDONE-IODINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03230058 | Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis | Phase 2/3 | 55 | Infection, Fungal | NATAMYCIN, VORICONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT07557966 | Intrastromal Injection of Fluconazole in Treatment of Fungal Keratitis | Not applicable | 40 | Safety, Efficacy, Intrastromal Injection, Fluconazole, Treatment, Fungal Keratitis | FLUCONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT03138785 | UVX as an Adjuvant in the Treatment of Fungal Keratitis | Not applicable | 20 | Treatment | ITRACONAZOLE, LEVOFLOXACIN, VORICONAZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): deaths from any cause | 1 of 165 | 0 of 165 | 330 | NCT05110001 | Trial comparisons |
| Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): serious adverse events | 31 of 165 | 36 of 165 | 330 | NCT05110001 | Trial comparisons |
| Topical Natamycin vs Topical Voriconazole: serious adverse events | 42 of 162 | 82 of 161 | 323 | NCT00996736 | Trial comparisons |
| Topical Natamycin vs Topical Voriconazole: Microbiological Cure at 6 Days | 23 of 155 | 69 of 144 | 299 | NCT00996736 | Trial comparisons |
| Intrastromal Voriconazole Plus Natamycin vs Natamycin Alone: deaths from any cause | 0 of 35 | 0 of 35 | 70 | NCT02731638 | Trial comparisons |
| Intrastromal Voriconazole Plus Natamycin vs Natamycin Alone: serious adverse events | 0 of 35 | 0 of 35 | 70 | NCT02731638 | Trial comparisons |
| Intrastromal Voriconazole Plus Natamycin vs Natamycin Alone: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus | 14 of 35 | 11 of 34 | 69 | NCT02731638 | Trial comparisons |
Papers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 15232472 | RESULT | 1 | PubMed |
| 42348235 | DERIVED | 1 | PubMed |
| 41561665 | DERIVED | 1 | PubMed |
| 39192339 | DERIVED | 1 | PubMed |
| 39011096 | DERIVED | 1 | PubMed |
| 35044972 | DERIVED | 1 | PubMed |
| 35024776 | DERIVED | 2 | PubMed |
| 33079921 | DERIVED | 1 | PubMed |
| 33031809 | DERIVED | 1 | PubMed |
| 32557558 | DERIVED | 2 | PubMed |
1 to 10 of 18
See all 18 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0033821
GET https://conductscience.org/api/diseases/v1/MONDO_0033821/drugs